Tags : Chi-Med

Weekly Snapshot

PharmaShots Weekly Snapshots (Jan 11- 15, 2021)

Novartis’ Ligelizumab (QGE031) Receives the US FDA’s Breakthrough Designation for Patients with Chronic Spontaneous Urticaria Published: Jan 15, 2020 | Tags: Novartis, ligelizumab, (QGE031), Receives, US, FDA, Breakthrough designation, chronic spontaneous urticaria (CSU) Philips Collaborates with Merck KGaA to Advance Personalized Fertility Treatment Published: Jan 15, 2020 | Tags: Philips, Merck KGaA, Personalized Fertility Treatment, […]Read More


Chi-Med and Inmagene Collaborate to Develop Therapies for Immunological Diseases

Shots: Chi-Med to receive ~$95M and ~$135M as development & commercial milestones along with royalties on commercialization of each drug candidates. Inmagene to get an exclusive option for four drug candidates solely for immunological diseases If Inmagene exercises the option, it will get the right to further develop, manufacture and commercialize the specific drug candidate […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshots (Dec 28- 31, 2020)

Sinopharm’s COVID-19 Vaccine Demonstrates 79% Efficacy in P-III Study Published: Dec 30, 2020 | Tags: COVID-19, Interim Analysis, New Coronavirus Inactivated Vaccine, P-lll Study, reports, results, Sinopharm Vertex Reports Health Canada’s Acceptance of Trikafta’s NDA for Priority Review to Treat Cystic Fibrosis Published: Dec 28, 2020 | Tags: CysticFibrosis, Drug, New, reports, Submission, Treatment, Trikafta, […]Read More


Eli Lilly Amends its 2013 Agreement with Chi-Med to Commercialize

Shots: Chi-Med to receive 70%-80% of Elunate sales in the form of royalties, manufacturing costs and service payments with no upfront regarding this amendment. Lilly will maintain the exclusive commercialization rights and will continue to consolidate the sales of Elunate in China while Chi-Med retains all rights to fruquintinib outside of China The agreement allows […]Read More


Chi-Med and BeiGene Collaborate to Evaluate the Combinations of Surufatinib

Shots: The two companies collaborated to evaluate the safety, tolerability and efficacy of Chi-Med’s surufatinib and fruquintinib, with BeiGene’s tislelizumab against multiple solid tumor cancer indications in the US, EU, China and Australia. Both the companies will mutually supply drug and other support Tislelizumab is an anti PD-1 mAb, specifically designed to minimize binding to […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (April 13 -17, 2020)

1. Sinovac Initiates the P-I Clinical Study for Vaccine Candidate Against COVID-19 Published: Apr 17, 2020 | Tags: Sinovac, Initiates, P-I, Clinical Study, Vaccine Candidate, Against, COVID-19 2. 1Health.io Launches Self-Collection Kits to Detect COVID-19 Published: Apr 16, 2020 | Tags: 1Health.io, Launches, Self-Collection Kits, Detect, COVID-19 3. Chi-Med’s Surufatinib Receives the US FDA’s Fast Track Designations […]Read More